Need for long-term follow-up in enterohemorrhagic Escherichia coli-Associated hemolytic uremic syndrome due to late-emerging sequelae

Clinical Infectious Diseases

Volumn 54, Issue 10, 2012, Pages 1413-1421

  Rosales, Alejandra ^a   Hofer, Johannes ^a   Zimmerhackl, Lotha Bernd ^a   Jungraithmayr, Therese C ^a   Riedl, Magdalena ^a   Giner, Thomas ^a   Strasak, Alexander ^a   Orth Höller, Dorothea ^a   Würzner, Reinhard ^a   Karch, Helge ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; COTRIMOXAZOLE; MACROLIDE; PENICILLIN DERIVATIVE; SHIGA TOXIN;

ANTIBIOTIC THERAPY; ARTICLE; AUSTRIA; CHILD; CHILDHOOD DISEASE; DIARRHEA; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; FOLLOW UP; GERMANY; GLOMERULUS FILTRATION RATE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RISK FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; AUSTRIA; BLOOD TRANSFUSION; CHILD, PRESCHOOL; DELAYED DIAGNOSIS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84860246424     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis196     Document Type: Article

References (40)

1. Gianantonio CA, Vitacco M, Mendilaharzu F, Gallo GE, Sojo ET. The hemolytic-uremic syndrome. Nephron 1973; 11:174-92.
2. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shigatoxin-producing Escherichia coli O104:H4 outbreak in Germany-preliminary report. N Engl J Med 2011; 365:1771-80.
3. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073-86.
4. Friedrich AW, Bielaszewska M, Zhang WL, et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002; 185:74-84.
5. Orth D, Grif K, Khan AB, Naim A, Dierich MP, Wurzner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn Microbiol Infect Dis 2007; 59:235-42.
6. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003; 290:1360-70.
7. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186:493-500.
8. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555-76.
9. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58:259-63.
10. Karch H, Tarr PI, Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 2005; 295:405-18.
11. Spizzirri FD, Rahman RC, Bibiloni N, Ruscasso JD, Amoreo OR. Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol 1997; 11:156-60.
12. Gagnadoux MF, Habib R, Gubler MC, Bacri JL, Broyer M. Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome. Clin Nephrol 1996; 46:39-41.
13. Garg AX, Salvadori M, Moist LM, Suri RS, Clark WF. Renal prognosis of toxigenic Escherichia coli infection. Kidney Int Suppl 2009: S38-41.
14. Milford DV, White RH, Taylor CM. Prognostic significance of proteinuria one year after onset of diarrhea-associated hemolyticuremic syndrome. J Pediatr 1991; 118:191-4.
15. Wong CS, Brandt JR. Risk of hemolytic uremic syndrome from antibiotic treatment of Escherichia coli O157:H7 colitis. JAMA 2002; 288:3111.
16. Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK, Hutchinson SJ. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001; 33:923-31.
17. Martin DL, Macdonald KL, White KE, Soler JT, Osterholm MT. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota. New Engl J Med 1990; 323:1161-7.
18. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008; 23:1749-60.
19. Oakes RS, Kirkham JK, Nelson RD, Siegler RL. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 2008; 23:1303-8.
20. Gould LH, Demma L, Jones TF, et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006. Clin Infect Dis 2009; 49:1480-5.
21. Kelles A, Vandyck M, Proesmans W. Childhood hemolytic-uremic syndrome: long-term outcome and prognostic features. Eur J Pediatr 1994; 153:38-42.
22. Siegler RL, Pavia AT, Christofferson RD, Milligan MK. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics 1994; 94:35-40.
23. Espie E, Grimont F, Mariani-Kurkdjian P, et al. Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996-2006. Pediatr Infect Dis J 2008; 27:595-601.
24. Hermos CR, Janineh M, Han LL, McAdam AJ. Shiga toxin-producing Escherichia coli in children: diagnosis and clinical manifestations of O157:H7 and non-O157:H7 infection. J Clin Microbiol 2011; 49:955-9.
25. Orth D, Grif K, Dierich MP, Wurzner R. Sorbitol-fermenting Shiga toxin-producing Escherichia coli O157: indications for an animal reservoir. Epidemiol Infect 2006; 134:719-23.
26. Fitzpatrick MM, Shah V, Trompeter RS, Dillon MJ, Barratt TM. Long-term renal outcome of childhood hemolytic uremic syndrome. Br Med J 1991; 303:489-92.
27. Ake JA, Jelacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005; 115:e673-80.
28. Siegler RL, Milligan MK, Burningham TH, Christofferson RD, Chang SY, Jorde LB. Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. J Pediatr 1991; 118:195-200.
29. Tonshoff B, Sammet A, Sanden I, Mehls O, Waldherr R, Scharer K. Outcome and prognostic determinants in the hemolytic uremic syndrome of children. Nephron 1994; 68:63-70.
30. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36:673-81.
31. Tarr PI. Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms of pathogenesis. Kidney Int Suppl 2009; 75:S29-32.
32. Rizzoni G, Claris-Appiani A, Edefonti A, et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988; 112:284-90.
33. Gianviti A, Perna A, Caringella A, et al. Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome. Am J Kidney Dis 1993; 22:264-6.
34. Loirat C, Sonsino E, Hinglais N, Jais JP, Landais P, Fermanian J. Treatment of the childhood haemolytic uraemic syndrome with plasma: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988; 2:279-85.
35. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25:83-177.
36. Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011; 378:1089-93.
37. Greinacher A, Friesecke S, Abel P, et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011; 378:1166-73.
38. Gianviti A, Tozzi AE, De PL, et al. Risk factors for poor renal prognosis in children with hemolytic uremic syndrome. Pediatr Nephrol 2003; 18:1229-35.
39. Renaud C, Niaudet P, Gagnadoux MF, Broyer M, Habib R. Haemolytic uraemic syndrome: prognostic factors in children over 3 years of age. Pediatr Nephrol 1995; 9:24-9.
40. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008; 111:624-32.